These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 18799049

  • 1. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis.
    Guignard S, Gossec L, Bandinelli F, Dougados M.
    Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S23-9. PubMed ID: 18799049
    [Abstract] [Full Text] [Related]

  • 2. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.
    JAMA; 2009 Feb 18; 301(7):737-44. PubMed ID: 19224750
    [Abstract] [Full Text] [Related]

  • 3. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Aug 18; 54(8):2368-76. PubMed ID: 16868999
    [Abstract] [Full Text] [Related]

  • 4. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2007 Jan 18; 56(1):13-20. PubMed ID: 17195186
    [Abstract] [Full Text] [Related]

  • 5. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun 18; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 6. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.
    Arthritis Rheum; 2009 Nov 18; 60(11):3180-9. PubMed ID: 19877027
    [Abstract] [Full Text] [Related]

  • 7. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA.
    Clin Exp Rheumatol; 2012 Nov 18; 30(1):31-8. PubMed ID: 22153557
    [Abstract] [Full Text] [Related]

  • 8. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases.
    Fujikawa K, Kawakami A, Hayashi T, Iwamoto N, Kawashiri SY, Aramaki T, Ichinose K, Tamai M, Arima K, Kamachi M, Yamasaki S, Nakamura H, Ida H, Origuchi T, Eguchi K.
    Mod Rheumatol; 2010 Feb 18; 20(1):86-9. PubMed ID: 19812889
    [Abstract] [Full Text] [Related]

  • 9. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM, Østergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, Poulsen UE, Espesen J, Schlemmer A, Graudal N, Kollerup G, Jensen DV, Madsen OR, Glintborg B, Christensen T, Lindegaard H, Bøhme W, Hansen A, Andersen AR, Hetland ML.
    J Rheumatol; 2014 Dec 18; 41(12):2352-60. PubMed ID: 25274894
    [Abstract] [Full Text] [Related]

  • 10. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, Hartkamp A, van de Laar MA, van Riel PL.
    Ann Rheum Dis; 2013 Jun 18; 72(6):895-900. PubMed ID: 22887849
    [Abstract] [Full Text] [Related]

  • 11. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.
    J Rheumatol; 2011 Jul 18; 38(7):1273-81. PubMed ID: 21572150
    [Abstract] [Full Text] [Related]

  • 12. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr 18; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 13. Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis.
    Inanc N, Direskeneli H.
    Rheumatol Int; 2006 Nov 18; 27(1):67-71. PubMed ID: 16896990
    [Abstract] [Full Text] [Related]

  • 14. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT, Changolkar AK, Scott McKenzie R.
    J Med Econ; 2012 Nov 18; 15(2):332-9. PubMed ID: 22168788
    [Abstract] [Full Text] [Related]

  • 15. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
    Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, Swiss Clinical Quality Management Physicians.
    Arthritis Rheum; 2009 May 15; 61(5):560-8. PubMed ID: 19405000
    [Abstract] [Full Text] [Related]

  • 16. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F, Anelli MG, Rinaldi A, Serafino L, Covelli M, Scioscia C, Iannone F, Lapadula G.
    Drug Dev Res; 2014 Nov 15; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [Abstract] [Full Text] [Related]

  • 17. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
    Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DP, British Society for Rheumatology Biologics Register Control Centre Consortium, BSRBR.
    Ann Rheum Dis; 2009 Feb 15; 68(2):209-15. PubMed ID: 18385277
    [Abstract] [Full Text] [Related]

  • 18. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.
    Moots RJ, Haraoui B, Matucci-Cerinic M, van Riel PL, Kekow J, Schaeverbeke T, Davis A, Tedeschi MA, Freundlich B, Chang DJ, Singh A.
    Clin Exp Rheumatol; 2011 Feb 15; 29(1):26-34. PubMed ID: 21345289
    [Abstract] [Full Text] [Related]

  • 19. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.
    Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA.
    Medicine (Baltimore); 2007 Jul 15; 86(4):242-251. PubMed ID: 17632266
    [Abstract] [Full Text] [Related]

  • 20. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
    Finckh A, Simard JF, Gabay C, Guerne PA, SCQM physicians.
    Ann Rheum Dis; 2006 Jun 15; 65(6):746-52. PubMed ID: 16339288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.